Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript

Zynex (ZYXI) reported a significant Q2 2025 financial downturn, with net revenue plummeting to $22.3 million from $49.9 million year-over-year, resulting in a $20 million net loss, primarily attributed to a temporary TRICARE payment suspension and strategic sales force reductions. In response, the company is implementing aggressive cost-cutting measures, including a 14% staff reduction, targeting $40 million in annualized savings and aiming for a return to positive cash flow by year-end. Leadership is undergoing significant change with the appointment of Steven Dyson as CEO and the CFO's resignation, leading to a suspension of quarterly guidance. Concurrently, Zynex submitted its NiCO laser pulse oximeter for FDA clearance in May, anticipating approval by December, positioning it to address accuracy issues in existing devices and potentially unlock the $1 billion co-oximetry market, while also actively working to refinance its $60 million convertible debt.

Analysis

Zynex, Inc. is undergoing a significant operational and financial reset, reflected in its Q2 2025 results where revenue plummeted to $22.3 million from $49.9 million year-over-year, driving a net loss of $20 million. This downturn is primarily attributed to the dual impact of an ongoing temporary payment suspension from its major payer, TRICARE, and a deliberate strategic pivot involving sales force reductions and adjusted shipping policies to improve payer mix. In response, the company has initiated aggressive cost-cutting measures, including a 14% staff reduction, targeting $40 million in annualized savings with the stated goal of returning to positive cash flow by year-end. Compounding the operational challenges are significant leadership changes, with a new CEO, Steven Dyson, set to join and the CFO resigning, which has prompted a suspension of financial guidance. Furthermore, a $60 million convertible debt is now a current liability due in May 2026, which the company is actively working to refinance. The key forward-looking catalyst is the NiCO laser pulse oximeter, submitted for FDA clearance in May. This product is positioned as a technologically superior solution to accuracy issues in the existing patient monitoring market, with a potential clearance timeline around the end of 2025, representing a crucial potential driver of future growth.

Key Decisions for Investors

• Investors should closely monitor near-term cash burn and the execution of the $40 million cost-reduction plan, as well as any progress on refinancing the $60 million convertible debt, which are critical to the company's financial stability.
• The primary long-term value driver is the NiCO pulse oximeter; therefore, tracking milestones in the FDA review process, including the expected information request in August and potential clearance near year-end, is essential.
• Given the leadership transition and suspension of guidance, await the strategic direction from the incoming CEO and the eventual reinstatement of financial forecasts to regain visibility into the company's recovery trajectory.
• Any news regarding the resolution of the TRICARE payment suspension represents a significant binary event for the stock, as a favorable outcome could rapidly improve revenue and sentiment, while a continued impasse remains a major operational and financial drag.